SASKATOON, Saskatchewan, November 28, 2025 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or “Corporation(TSXV: PCRX) today announced a leadership transition in which Paul Dale has been appointed President and Chief Operating Officer, effective December 1, 2025, as Calvin Leroux steps down as President to begin a one-year appointment as a strategic advisor to the Chief Executive Officer.
Mr. Dale has served as PharmaCorp's Chief Operating Officer since its inception and will now assume expanded leadership responsibilities as PharmaCorp moves forward with its national expansion strategy. “Paul’s appointment strengthens the continuity of our operating model and our confidence in his leadership,” said Alan Simpson, executive chairman of PharmaCorp. “His experience leading complex retail organizations and his consistent execution of all our acquisition and integration efforts make him uniquely suited for this expanded mandate.”
Mr. Leroux's term ends on November 30, 2025. In his new advisory role, he will assist in the transition of responsibilities, provide input on strategic initiatives and continue to provide advice on matters affecting PharmaChoice Canada. “Kelvin was instrumental in the early development of PharmaCorp and in strengthening our relationship with PharmaChoice Canada,” added Mr. Simpson. “We are pleased that he will continue to support PharmaCorp in an advisory capacity.”
PharmaCorp is also pleased to announce that Sophia Sigler will join the corporation as Director of Business Development, effective December 1, 2025. Ms. Sigler will lead PharmaCorp's business development initiatives, including sourcing acquisition opportunities, managing transaction flow, coordinating due diligence and supporting pharmaceutical partners through cross-ownership and succession structures.
About PharmaCorp Rx Inc.
PharmaCorp is a Canadian pharmacy acquisition and ownership platform that aims to empower pharmacists as equity partners and support the succession of retired pharmacy owners. Through a combination of capital, strategic support and operational expertise, PharmaCorp is building a national network of community pharmacies under the PharmaChoice Canada brand. PharmaCorp currently operates seven PharmaChoice Canada-branded pharmacies and will continue to acquire both PharmaChoice Canada-branded pharmacies and independent pharmacies across Canada, rebranding non-banner pharmacies under the PharmaChoice Canada platform in line with its strategic alliance with PharmaChoice Canada. PharmaCorp shares trade on the TSX Venture Exchange under the symbol PCRX.
PharmaCorp actively encourages discussions with pharmacy owners regarding succession or divestment issues. For more information about our program and purchasing process, visit www.PharmaCorpRx.ca or contact our team confidentially. We are committed to a smooth transition that protects your legacy and serves your community.
For more information contact:
Investor Relations
[email protected]
Tel: (306) 536-3771
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking information: This press release contains “forward-looking information” regarding the Corporation within the meaning of applicable Canadian securities laws. All statements other than statements of historical fact included herein constitute forward-looking information. In particular, this press release contains forward-looking information with respect to: the expected responsibilities and contributions of Mr. Dale, Mr. Leroux and Ms. Sigler; the expected impact of the change in management on the Corporation's operations, strategy and growth; and the Corporation's goal to continue to acquire pharmacies as they enter the market and to operate such pharmacies under the PharmaChoice Canada brand. This forward-looking information reflects current beliefs and is based on information currently available to management of the Corporation and on assumptions that the Corporation believes to be reasonable. These assumptions include, but are not limited to: the volume of acquisition opportunities presented to the Corporation is equal to or greater than historical volumes; and the continued supply of pharmacies for purchase by the Corporation at prices satisfactory to the Corporation and the Corporation's ability to purchase such pharmacies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Corporation to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to obtain board, third party or regulatory approvals; competition; changes in legislation, including regulation of pharmacies, affecting the Corporation; timing and availability of external financing on acceptable terms; findings from economic assessments and assessments; and shortages of skilled, skilled labor or loss of key individuals. A description of additional risk factors that could cause actual results to differ materially from forward-looking information can be found in the Corporation's disclosure documents on SEDAR+ at: www.sedarplus.ca. Although the Corporation has attempted to identify important risks and factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as expected, estimated or intended. Readers are cautioned that the above list of factors is not exhaustive. Readers are also cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations on which they are based will occur. The forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release reflects the Corporation's expectations as of the date of this press release and, accordingly, are subject to change after such date. However, the Corporation expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.
